Literature DB >> 14965362

Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells.

Shun-ichiro Okumura1, Hiroko Baba, Tatsuro Kumada, Koji Nanmoku, Hirofumi Nakajima, Yasushi Nakane, Koshiro Hioki, Kazuhiro Ikenaka.   

Abstract

The present study was directed towards the identification of novel factors involved in the transformation process leading to the formation of gastric cancer. A cDNA library from human gastric cancer cells was constructed using a retroviral vector. Functional cloning was performed by screening for transformation activity in transduced NIH3T3 cells. Six cDNA clones were isolated, including one encoding the elongation factor 1alpha subunit, which was already known to play a role in tumorigenesis. One cDNA (clone 56.2), which was repeatedly isolated during the course of screening, encoded a protein identical to a G-protein-coupled receptor protein, GPR35. In addition, another cDNA clone (72.3) was found to be an alternatively spliced product of the GPR35 gene, whereby 31 amino acids were added to the N-terminus of GPR35. Hence, the proteins encoded by clones 56.2 and 72.3 were designated GPR35a and GPR35b, respectively. RT-PCR experiments revealed that GPR35 gene expression is low or absent in surrounding non-cancerous regions, while both mRNAs were present in all of the gastric cancers examined. The level of 72.3-encoded mRNA was consistently significantly higher than that of 56.2 encoded mRNA. An expression pattern similar to that observed in gastric cancers was detected in normal intestinal mucosa. Based on the apparent transformation activities of the two GPR35 clones in NIH3T3 cells, and the marked up-regulation of their expression levels in cancer tissues, it is speculated that these two novel isoforms of GPR35 are involved in the course of gastric cancer formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14965362     DOI: 10.1111/j.1349-7006.2004.tb03193.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  33 in total

1.  Application of machine learning algorithms to predict coronary artery calcification with a sibship-based design.

Authors:  Yan V Sun; Lawrence F Bielak; Patricia A Peyser; Stephen T Turner; Patrick F Sheedy; Eric Boerwinkle; Sharon L R Kardia
Journal:  Genet Epidemiol       Date:  2008-05       Impact factor: 2.135

2.  Crucial positively charged residues for ligand activation of the GPR35 receptor.

Authors:  Pingwei Zhao; Tom R Lane; Helen G L Gao; Dow P Hurst; Evangelia Kotsikorou; Long Le; Eugen Brailoiu; Patricia H Reggio; Mary E Abood
Journal:  J Biol Chem       Date:  2013-12-17       Impact factor: 5.157

3.  TGFβ-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme.

Authors:  Dhiman Ghosh; Ilya V Ulasov; LiPing Chen; Lualhati E Harkins; Karolina Wallenborg; Parvinder Hothi; Steven Rostad; Leroy Hood; Charles S Cobbs
Journal:  Stem Cells       Date:  2016-07-04       Impact factor: 6.277

4.  Adopting an Orphan: How Could GRP35 Contribute to Angiotensin II-Dependent Hypertension?

Authors:  Cameron G McCarthy; Camilla F Wenceslau
Journal:  Am J Hypertens       Date:  2018-08-03       Impact factor: 2.689

5.  GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump.

Authors:  Georg Schneditz; Joshua E Elias; Ester Pagano; M Zaeem Cader; Svetlana Saveljeva; Kathleen Long; Subhankar Mukhopadhyay; Maryam Arasteh; Trevor D Lawley; Gordon Dougan; Andrew Bassett; Tom H Karlsen; Arthur Kaser; Nicole C Kaneider
Journal:  Sci Signal       Date:  2019-01-01       Impact factor: 8.192

6.  The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35.

Authors:  Amanda E MacKenzie; Gianluigi Caltabiano; Toby C Kent; Laura Jenkins; Jennifer E McCallum; Brian D Hudson; Stuart A Nicklin; Lindsay Fawcett; Rachel Markwick; Steven J Charlton; Graeme Milligan
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

7.  Structure-activity relationships of benzothiazole GPR35 antagonists.

Authors:  Manahil M Abdalhameed; Pingwei Zhao; Dow P Hurst; Patricia H Reggio; Mary E Abood; Mitchell P Croatt
Journal:  Bioorg Med Chem Lett       Date:  2016-12-05       Impact factor: 2.823

8.  GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17?

Authors:  Soo-Jin Park; Seung-Jin Lee; So-Yeon Nam; Dong-Soon Im
Journal:  Br J Pharmacol       Date:  2017-12-08       Impact factor: 8.739

9.  A Cell-Surface Membrane Protein Signature for Glioblastoma.

Authors:  Dhimankrishna Ghosh; Cory C Funk; Juan Caballero; Nameeta Shah; Katherine Rouleau; John C Earls; Liliana Soroceanu; Greg Foltz; Charles S Cobbs; Nathan D Price; Leroy Hood
Journal:  Cell Syst       Date:  2017-03-29       Impact factor: 10.304

10.  Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists.

Authors:  Huayun Deng; Haibei Hu; Shizhang Ling; Ann M Ferrie; Ye Fang
Journal:  ACS Med Chem Lett       Date:  2012-01-17       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.